Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Marks

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Expert Opinion on Pharmacotherapy|June 12, 2009
Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressantsChi-Un Pae, David M Marks, Ashwin A Patkar, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|January 8, 2009
Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopauseChi-Un Pae, Min-Hyeon Park, David M Marks, et al.
Current Neuropharmacology|June 2, 2010
Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promiseDavid M Marks, Manan J Shah, Ashwin A Patkar, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 10, 2015
Marked gender differences in progression of mild cognitive impairment over 8 yearsKatherine A Lin, Kingshuk Roy Choudhury, Bharath G Rathakrishnan, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 13, 2009
History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgiaChi-Un Pae, Prakash S Masand, David M Marks, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|July 11, 2008
An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical featuresChi-Un Pae, Prakash S Masand, Kathleen Peindl, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|January 23, 2009
History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled studyDavid M Marks, Changsu Han, Stan Krulewicz, et al.
Clinical Neuropharmacology|July 22, 2009
Milnacipran: beyond a role of antidepressantChi-Un Pae, David M Marks, Manan Shah, et al.
Expert Opinion on Drug Safety|November 6, 2008
Paroxetine: safety and tolerability issuesDavid M Marks, Min-Hyeon Park, Byung-Joo Ham, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|April 22, 2009
History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled releaseChi-Un Pae, Prakash S Masand, David M Marks, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Expert Opinion on Pharmacotherapy|June 12, 2009
Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressantsChi-Un Pae, David M Marks, Ashwin A Patkar, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|January 8, 2009
Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopauseChi-Un Pae, Min-Hyeon Park, David M Marks, et al.
Current Neuropharmacology|June 2, 2010
Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promiseDavid M Marks, Manan J Shah, Ashwin A Patkar, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 10, 2015
Marked gender differences in progression of mild cognitive impairment over 8 yearsKatherine A Lin, Kingshuk Roy Choudhury, Bharath G Rathakrishnan, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|May 13, 2009
History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgiaChi-Un Pae, Prakash S Masand, David M Marks, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|July 11, 2008
An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical featuresChi-Un Pae, Prakash S Masand, Kathleen Peindl, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|January 23, 2009
History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled studyDavid M Marks, Changsu Han, Stan Krulewicz, et al.
Clinical Neuropharmacology|July 22, 2009
Milnacipran: beyond a role of antidepressantChi-Un Pae, David M Marks, Manan Shah, et al.
Expert Opinion on Drug Safety|November 6, 2008
Paroxetine: safety and tolerability issuesDavid M Marks, Min-Hyeon Park, Byung-Joo Ham, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|April 22, 2009
History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled releaseChi-Un Pae, Prakash S Masand, David M Marks, et al.
Pageof 4